These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 25139456

  • 1. Prognostic value of midregional pro-A-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with stable coronary heart disease followed over 8 years.
    Karakas M, Jaensch A, Breitling LP, Brenner H, Koenig W, Rothenbacher D.
    Clin Chem; 2014 Nov; 60(11):1441-9. PubMed ID: 25139456
    [Abstract] [Full Text] [Related]

  • 2. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1973-80. PubMed ID: 17996563
    [Abstract] [Full Text] [Related]

  • 3. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
    van Hateren KJ, Alkhalaf A, Kleefstra N, Groenier KH, de Jong PE, de Zeeuw D, Gans RO, Struck J, Bilo HJ, Gansevoort RT, Bakker SJ.
    Clin Chem; 2012 Jan 13; 58(1):293-7. PubMed ID: 21948291
    [Abstract] [Full Text] [Related]

  • 4. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E, Brueckmann M, Lang S, Kälsch T, Haghi D, Sueselbeck T, Dempfle CE, Borggrefe M.
    Int J Cardiol; 2008 Aug 18; 128(2):244-9. PubMed ID: 17673312
    [Abstract] [Full Text] [Related]

  • 5. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.
    Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, Morgenthaler NG, Bergmann A, Davies JE, Ng LL.
    J Am Coll Cardiol; 2008 May 13; 51(19):1857-64. PubMed ID: 18466800
    [Abstract] [Full Text] [Related]

  • 6. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J, Potocki M, Murray K, Breidthardt T, Ziller R, Mosimann T, Klima T, Hoeller R, Moehring B, Sou SM, Rubini Gimenez M, Morgenthaler NG, Mueller C.
    Heart; 2012 Oct 13; 98(20):1518-22. PubMed ID: 22865868
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
    Pervez MO, Winther JA, Brynildsen J, Strand H, Christensen G, Høiseth AD, Myhre PL, Røysland R, Lyngbakken MN, Omland T, Røsjø H.
    Biomarkers; 2018 Nov 13; 23(7):654-663. PubMed ID: 29733687
    [Abstract] [Full Text] [Related]

  • 8. Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B-type natriuretic peptide (BNP) and N-terminal proBNP.
    Chenevier-Gobeaux C, Guerin S, André S, Ray P, Cynober L, Gestin S, Pourriat JL, Claessens YE.
    Clin Chem; 2010 Nov 13; 56(11):1708-17. PubMed ID: 20813917
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease.
    Ahluwalia N, Blacher J, Szabo de Edelenyi F, Faure P, Julia C, Hercberg S, Galan P.
    Atherosclerosis; 2013 Jun 13; 228(2):478-84. PubMed ID: 23582589
    [Abstract] [Full Text] [Related]

  • 10. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure.
    Tan ESJ, Chan SP, Liew OW, Chong JPC, Gerard Leong KT, Daniel Yeo PS, Ong HY, Jaufeerally F, Sim D, Ling LH, Lam CSP, Richards AM.
    JACC Heart Fail; 2024 Mar 13; 12(3):461-474. PubMed ID: 37897459
    [Abstract] [Full Text] [Related]

  • 11. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
    Rothenbacher D, Koenig W, Brenner H.
    Arch Intern Med; 2024 Mar 13; 166(22):2455-60. PubMed ID: 17159010
    [Abstract] [Full Text] [Related]

  • 12. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.
    Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA.
    JAMA; 2007 Jan 10; 297(2):169-76. PubMed ID: 17213400
    [Abstract] [Full Text] [Related]

  • 13. NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation.
    Niccoli G, Conte M, Marchitti S, Montone RA, Fracassi F, Grippo R, Roberto M, Burzotta F, Trani C, Leone AM, Bianchi F, Di Castro S, Volpe M, Crea F, Rubattu S.
    Cardiovasc Revasc Med; 2016 Jan 10; 17(3):162-8. PubMed ID: 26987266
    [Abstract] [Full Text] [Related]

  • 14. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D, Berger R, Struck J, Gleiss A, Hammer A, Morgenthaler NG, Bergmann A, Huelsmann M, Pacher R.
    J Am Coll Cardiol; 2009 May 12; 53(19):1783-90. PubMed ID: 19422985
    [Abstract] [Full Text] [Related]

  • 15. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
    Bégué C, Mörner S, Brito D, Hengstenberg C, Cleland JGF, Arbustini E, Galve E, Wichter T, Richter A, Golmard JL, Bernard M, Dubourg O, Komajda M, Charron P, Isnard R.
    Heart; 2020 Feb 12; 106(3):196-202. PubMed ID: 31350276
    [Abstract] [Full Text] [Related]

  • 16. Plasma natriuretic peptides and incidence of subtypes of ischemic stroke.
    Berntsson J, Zia E, Borné Y, Melander O, Hedblad B, Engström G.
    Cerebrovasc Dis; 2014 Feb 12; 37(6):444-50. PubMed ID: 25060145
    [Abstract] [Full Text] [Related]

  • 17. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U, Dahlström U, Rehfeld JF, Goetze JP.
    J Card Fail; 2013 Jan 12; 19(1):31-9. PubMed ID: 23273592
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study.
    Gaborit FS, Kistorp C, Kümler T, Hassager C, Tønder N, Iversen K, Hansen PM, Kamstrup PR, Faber J, Køber L, Schou M.
    Biomarkers; 2020 May 12; 25(3):248-259. PubMed ID: 32126847
    [Abstract] [Full Text] [Related]

  • 19. Plasma C-terminal pro-endothelin-1 and the natriuretic pro-peptides NT-proBNP and MR-proANP in very preterm infants with patent ductus arteriosus.
    Letzner J, Berger F, Schwabe S, Benzing J, Morgenthaler NG, Bucher HU, Bührer C, Arlettaz R, Wellmann S.
    Neonatology; 2012 May 12; 101(2):116-24. PubMed ID: 21952518
    [Abstract] [Full Text] [Related]

  • 20. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL.
    Eur Heart J; 2012 Sep 12; 33(17):2197-205. PubMed ID: 22645194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.